Neutrophil CD64 as a Diagnostic Marker of Sepsis in Neonates

Elawady, Sanaa; Botros, Shahira K. A.; Sorour, Ashraf E.; Ghany, Eman Abdel Ghany Abdel; El-Batran, Gamal; Ali, Raghdaa

doi:10.2310/jim.0000000000000060

Cited by 39 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the expression level of CD64 could be used as a basis to determine bacterial infections in patients with prostatitis. These findings coincide with previous reports . Thus, CD64 expression highly correlated with bacterial infection, and a high CD64 level in the prostate liquid could effectively suggest the possibility of bacterial infection.…”

Section: Discussionsupporting

confidence: 92%

“…FcγR I (CD64) is a 72‐kDa transmembrane glycoprotein, the highest affinity receptor of immunoglobulin (IgG), and a member of the immunoglobulin superfamily . CD64 is primarily distributed on the surfaces of monocytes, macrophages, and activated neutrophils in the peripheral blood; it is involved in the phagocytosis of immune cells toward bacteria and immune complexes and plays an important role in the body's defense functions …”

Section: Introductionmentioning

confidence: 99%

“…CD64 reportedly acts as a diagnostic marker of sepsis in neonates, systemic infection and necrotizing enterocolitis in pre‐term infants, infection after chemotherapy in patients with hematologic malignancies, neonatal infection, bacterial infection, post‐operative surgical patients and critically ill patients, intestinal macrophages, and acetaminophen‐induced acute liver failure …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Determination of CD64 for the Diagnosis of Bacterial Chronic Prostatitis

Zhou

et al. 2015

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of CD64 for the Diagnosis of Bacterial Chronic Prostatitis

Zhou

et al. 2015

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…1x10 4 BM cells were seeded in MethoCult TM medium (StemCell Technologies) containing 50 ng/mL murine rSCF, 10 ng/mL murine rIL-3, and 10 ng/mL murine rIL-6 into 6-well plates. Cells were incubated at 37°C for seven days and colonies per well were counted.…”

Section: Colony Formation Assaymentioning

confidence: 99%

“…1 A fine-tuned regulation of the number of circulating neutrophils together with local control of neutrophil activation is important to balance pathogen defense, inflammation and tissue integrity. Imbalances are associated with infection and a number of inflammatory diseases including rheumatoid arthritis, 2 acute myocardial infarction, 3 sepsis, 4 or cancer. 5 In patients suffering from these diseases, TIMP-1 plasma levels are often elevated, and correlate with poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

TIMP-1 signaling via CD63 triggers granulopoiesis and neutrophilia in mice

et al. 2015

View full text Add to dashboard Cite

© F e r r a t a S t o r t i F o u n d a t i o nrent study, we investigated whether TIMP-1 affects neutrophil homeostasis. We show that TIMP-1 signaling via CD63 triggered granulopoiesis in the bone marrow (BM) resulting in increased systemic neutrophil blood counts. Our findings reveal a new function of TIMP-1 on immune cell homeostasis, and may provide a link to the frequently described correlation of high TIMP-1 levels with inflammatory diseases in the clinic. Methods Animal experimentsAnimal experiments were performed in compliance with the guidelines of the Tierschutzgesetz des Freistaates Bayern and approved by the Regierung von Oberbayern. For TIMP-1-secreting tumors, 2x10 6 HT1080 cells were subcutaneously injected into the nuchal fold of CD1 nu/nu mice and tumors were grown over ten days to a diameter of approximately 1 cm. Tumor size was monitored with a caliper. For adenoviral transduction, 3x10 9 ifu were intravenously injected, as previously described. 22 Recombinant TIMP-1 protein was applied in LPS-free PBS by a single intraperitoneal (i.p.) injection of 2 mg/kg, as previously described. 22 Mice were killed with CO 2 , blood was collected from the vena cava inferior using EDTA-coated syringes, and BM cells were obtained by flushing femurs and tibias with PBS. Flow cytometryAbsolute quantification of blood neutrophils occurred in BD trucount TM tubes according to the manufacturer´s instructions. Briefly, antibody-cocktail was mixed with 50 mL fresh blood in trucount TM tubes and incubated for 15 min at RT. Subsequently, 450 mL FACS TM lysing solution (BD Bioscience) were added and incubated for 30 min at RT to lyse erythrocytes and fix the sample. For staining of BM, femurs and tibias were flushed with PBS and the obtained cell suspension was stained as blood. Samples were measured on a FACS Canto TM II flow cytometer (BD) and analyzed using FlowJo software. Immunohistochemical staining of neutrophilsFor immunohistochemical analysis of BM, femurs were freed from tissue, fixed in 4% paraformaldehyde for 20 h, de-calcified in 0.5 M EDTA for five days, dehydrated and embedded into paraffin. Ly6G-positive cells were stained on 4 mm sections, as previously described. 22 Colony formation assayBone marrow cells were harvested from AdCtrl or AdT1-transduced mice and erythrocytes were removed with RBC lysis buffer (eBioscience). 1x10 4 BM cells were seeded in MethoCult TM medium (StemCell Technologies) containing 50 ng/mL murine rSCF, 10 ng/mL murine rIL-3, and 10 ng/mL murine rIL-6 into 6-well plates. Cells were incubated at 37°C for seven days and colonies per well were counted. For each mouse, analysis was performed in duplicates, and a total of 5 mice per group were analyzed. 32Dcl3 differentiation assay 32Dcl3 cells were seeded at a density of 8x10 5 cells/mL in IL3-free medium supplemented with 100 ng/mL murine G-CSF (Peptrotech) +/-1000 ng/mL rTIMP-1. Every two days, medium was replaced by fresh medium containing 50 ng/mL G-CSF +/-1000 ng/mL rTIMP-1. At the indicated time points, cells were c...

show abstract

Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?

Průcha

Zazula

Rußwurm

2016

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Sepsis is the most frequent cause of death in noncoronary intensive care units. In the past 10 years, progress has been made in the early identification of septic patients and their treatment. These improvements in support and therapy mean that mortality is gradually decreasing, however, the rate of death from sepsis remains unacceptably high. Immunotherapy is not currently part of the routine treatment of sepsis. Despite experimental successes, the administration of agents to block the effect of sepsis mediators failed to show evidence for improved outcome in a multitude of clinical trials. The following survey summarizes the current knowledge and results of clinical trials on the immunotherapy of sepsis and describes the limitations of our knowledge of the pathogenesis of sepsis. Administration of immunomodulatory drugs should be linked to the current immune status assessed by both clinical and molecular patterns. Thus, a careful daily review of the patient's immune status needs to be introduced into routine clinical practice giving the opportunity for effective and tailored use of immunomodulatory therapy.

show abstract

Neutrophil CD64 as a Diagnostic Marker of Sepsis in Neonates

Abstract: CD64 expression on neutrophils increases significantly in neonates with sepsis and can be considered a useful diagnostic marker for early diagnosis of neonatal infection as a single determination compared with other inflammatory markers.

Cited by 39 publications

References 21 publications

Determination of CD64 for the Diagnosis of Bacterial Chronic Prostatitis

Determination of CD64 for the Diagnosis of Bacterial Chronic Prostatitis

TIMP-1 signaling via CD63 triggers granulopoiesis and neutrophilia in mice

Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?

Contact Info

Product

Resources

About